Investor brief.
A short, honest read on what NSAS is, where we are, and what capital deployed at this stage actually does. Open to conversations with mission-aligned investors who bring more than money to the table.
The one-paragraph version
Neuro Scan AI Solutions is a Finnish clinical AI company building real-time epileptic seizure detection from scalp EEG. The detection engine is dataset-validated on the public CHB-MIT benchmark with 98.7% window-level classification accuracy under leave-one-patient-out cross-subject splits. The mobile application (Expo/React Native) and the reference 22-channel hardware are built. Ethics-committee submissions are open at four hospitals — two in Turkey, one in Helsinki, one in the United States — to launch the first live clinical pilots. CE-MDR submission follows pilot data. No live patient EEG has been processed yet; we are explicit about that on every page of this site.
Why this stage
Clinical AI gets harder to fund just before the moment it gets easier to scale. The work between "dataset paper" and "first hospital deployment" is unglamorous: ethics submissions, QMS documentation, on-site clinician training, post-market surveillance scaffolding. It is also where most early-stage clinical AI dies, because that bridge is rarely capitalized properly.
We are at exactly that bridge. The science is done. The product is built. The ethics queue is moving. Capital deployed at this point shortens the time-to-first-pilot, not the time-to-first-prototype.
Where we are — the same picture as the home page
Algorithm validated
CHB-MIT · LOO · cross-subject · 98.7% accuracy · 75.34% sensitivity · 0.1 FAR/24h.
Mobile app shipped
Patient + clinician flows, push alerts, event replay, GDPR-compliant exports.
Hardware reference
22-channel scalp EEG, standard-interface compatible. Demo-ready.
Ethics review · 4 sites
2 hospitals Turkey · 1 Helsinki · 1 USA. Partners published on consent.
First clinical pilots
Real EEG, real clinicians. Quarterly performance review per site.
CE-MDR submission
Class IIa SaMD pathway. ISO 13485 QMS in build. Depends on pilot data.
Business model
Two revenue streams, both fully under our control once the platform is in clinical deployment:
The wireless wearable headset, supplied to hospitals, EMUs, and research institutions. Per-site licensing and bulk pricing are negotiated at pilot or distributor level.
The clinician dashboard, mobile app, analysis pipeline, and software updates. SaaS-style ARR that scales linearly with deployed device count.
Capitalization to date
€40,000 founding capital, self-financed by Dr. Yıldırım. To date the company has not raised external equity. The capital deployed so far has funded company incorporation, the engineering work that produced the mobile app and reference hardware, the CHB-MIT validation cycle, and the ethics-committee submission packages currently in review.
Indicative revenue trajectory
The phased outlook below reflects the working business-plan assumptions. Each phase is gated by a clinical / regulatory milestone, not by a calendar date — we will not anchor years that we cannot defend to investors in conversation. Full P&L statement, balance-sheet projection, unit economics, and downside scenarios are available under NDA.
| Phase | Devices deployed | Hardware | Subscription | Total revenue |
|---|---|---|---|---|
| A · First pilot year | ~35 | €280K | €2.6K | ~€283K |
| B · CE-MDR + early distribution | ~1,250 | €10M | €158K | ~€10.2M |
| C · Pan-European rollout | ~12,500 | €100M | €2.8M | ~€102.8M |
| D · Global (incl. North America) | ~36,250 | €290M | €11.6M | ~€301.6M |
Addressable European market is sized at approximately €98 billion; the four-year trajectory above corresponds to capturing roughly €414.8M of that — under 0.5% market share. Whether that proves conservative or optimistic depends entirely on clinical-pilot signal quality and the speed of the regulatory cycle.
What capital at this stage funds
Indicative allocation. Final terms and percentages are subject to round structure and lead-investor input.
Milestones we will be measured on
- Next 6 months: close ethics-committee approval at the first of the four pilot sites; first patient under monitoring within 30 days of approval.
- 6–12 months: two sites live; first quarterly performance report on real clinical data; preliminary safety and effectiveness signals reported transparently.
- 12–18 months: all four sites live; CE-MDR technical documentation submission-ready; ISO 13485 certification audit booked.
- 18–24 months: CE-MDR submitted; commercial pilot conversations with named distributors open.
We will publish progress on milestones publicly — pilot site count, time-to-detection on real EEG, FAR on real data, named partners as consents land. The same numbers will go to investors and to the open press.
Team
Dr. Serkan Yıldırım, PhD — Founder & CEO. Computer Sciences, 25+ years in software development, AI, and team leadership. Author of the research that the NSAS detection engine is built on.
Erdal Çakıroğlu — Co-founder, Data Specialist. Software Engineering (Melbourne Polytechnic); senior data architecture, database, and embedded-systems experience. Owns the data layer and the security envelope around clinical data.
Göktuğ Yıldırım — Co-founder, Marketing & Sales. Drives partner outreach, go-to-market, and external communications.
Prof. Dr. Meryem Aslı Tuncer, MD — Medical Advisor. Professor of Neurology at Hacettepe University Faculty of Medicine, Ankara; 20+ years clinical practice with a Master's in Clinical Neuroimmunology. She gate-keeps the clinical methodology and signs off on what gets shipped to hospitals.
Novamio Technologies LLT (United States) — contracted engineering partner under a formal cooperation protocol. Embedded-firmware and mobile-application engineering bench, alongside the Finland team.
Clinical Affairs Lead, Senior ML Engineer, Mobile Engineer (RN), and QA/RA Engineer roles are open and detailed on the careers page. The lead-hire shortlists for each of these roles are warm; we hire when the right person appears, not on a calendar.
How to engage
For substantive investor conversations: clinical@nsai.fi. Please include your fund, ticket-size range, healthcare/clinical-AI track record, and what you want NSAS to look like in 24 months. We respond to credible inbound within five business days.
We are particularly interested in: funds with operating partners in neurology, medical device, or regulated AI; strategic investors with hospital-distribution networks in the EU or US; clinical foundations whose mission overlaps ours.